October 2019

Panelists review the delicate process of introducing a new medication to a treatment regimen and the creative endeavors employed to improve adherence.

In an interview with NeurologyLive, Andrew S. Feigin, MD, details ongoing trials that aim to treat Huntington disease, including the notable SIGNAL trial.

Bogged down by a decades-long chase for a common pathology, investigators exploring alternative and complimentary theories are pushing to extend their time in the spotlight.

Although the indication of pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage psychosis symptoms.

The benefits of lowering systolic blood pressure for stroke prevention and reducing poststroke disability are numerous, but the ideal target remains elusive.

Reisa Sperling, MD sat down with NeurologyLive to discuss why she thinks investigational drugs for Alzheimer disease are failing, and what she feels are the most promising treatment avenues.

Krithika Subramanian, PhD discusses the orexin receptor pathway, signals within orexin receptors, and much more surrounding the clinical application of orexin receptor antagonists.

NeurologyLive's editor in chief Stephen D. Silberstein, MD, discusses the importance of considering treatment contraindications in the context of individual patients.